Infectious Diseases drugs

68 results

  • aemcolo

    (Rifamycin)
    RedHill Biopharma Ltd
    AEMCOLO is indicated for treating travelers' diarrhea caused by non-invasive strains of Escherichia coli in adults. It is not recommended for diarrhea with fever or bloody stools, or due to other pathogens. Use is limited to proven or strongly suspected infections to prevent drug resistance.

  • albuked

    (Albumin (Human))
    KEDRION BIOPHARMA, INC.
    Albuked 5 is indicated for the emergency treatment of hypovolemic shock, burn therapy, cardiopulmonary bypass, acute liver failure, and sequestration of protein-rich fluids. It aids in expanding circulating blood volume and maintaining colloid osmotic pressure in various clinical scenarios.

  • anthim

    (obiltoxaximab)
    Elusys Therapeutics, Inc.
    ANTHIM is indicated for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis in adults and pediatric patients, used in combination with antibacterial drugs. Its prophylactic use is limited to situations where benefits exceed the risks of hypersensitivity and anaphylaxis.

  • apretude

    (Cabotegravir)
    ViiV Healthcare Company
    APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk. A negative HIV-1 test must be confirmed before starting APRETUDE.

  • avycaz

    (ceftazidime, avibactam)
    Allergan, Inc.
    AVYCAZ (ceftazidime and avibactam) is indicated for treating complicated intra-abdominal and urinary tract infections, including pyelonephritis, as well as hospital-acquired and ventilator-associated bacterial pneumonia. It targets susceptible gram-negative bacteria in adult and pediatric patients (≥31 weeks gestational age).

  • besivance

    (Besifloxacin)
    Bausch & Lomb Incorporated
    BESIVANCE (besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible bacteria, including Haemophilus influenzae and various Staphylococcus, Streptococcus, and Moraxella species. Efficacy for some organisms was studied in fewer than 10 infections.

  • beyfortus

    (nirsevimab)
    Sanofi Pasteur Inc.
    BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children up to 24 months at risk of severe RSV disease during their second RSV season.

  • biktarvy

    (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
    Gilead Sciences, Inc.
    BIKTARVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg, either as a complete regimen for those with no antiretroviral treatment history or as a replacement for those who are virologically suppressed on a stable regimen without resistance issues.

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated as a complete regimen for treating HIV-1 infection in adults and adolescents (12 years and older, weighing at least 35 kg) who are virologically suppressed on a stable antiretroviral regimen, with no history of treatment failure or resistance to cabotegravir or rilpivirine.

  • complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.